Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2676
WisdomTree Bitcoin Fund
BTCW
$190M
| $697K | ﹤0.01% |
+6,100
| New | +$637K |
2025 Q2
0 quarters
|
|
2677
State Street SPDR S&P Metals & Mining ETF
XME
$4.22B
| $692K | ﹤0.01% |
+10,300
| New | +$611K |
2025 Q2
0 quarters
|
|
2678
Ovid Therapeutics
OVID
$480M
| $691K | ﹤0.01% |
2,095,309
+1,071,509
| +105% | +$323K |
2021 Q3
15 quarters
|
|
2679
State Street SPDR S&P 400 Mid Cap Value ETF
MDYV
$2.71B
| $691K | ﹤0.01% |
8,700
-9,600
| -52% | -$727K |
2023 Q3
7 quarters
|
|
2680
Hycroft Mining Holding Corp
HYMC
$1.79B
| $690K | ﹤0.01% |
220,579
+119,900
| +119% | +$392K |
2021 Q2
16 quarters
|
|
2681
D-Market Electronic Services & Trading
HEPS
$1.17B
| $690K | ﹤0.01% |
255,700
-91,800
| -26% | -$249K |
2022 Q2
12 quarters
|
|
2682
Vinci Compass Investments Ltd
VINP
$758M
| $690K | ﹤0.01% |
71,332
+300
| +0.4% | +$2.89K |
2022 Q2
12 quarters
|
|
2683
Quanterix
QTRX
$155M
| $686K | ﹤0.01% |
103,200
-99,721
| -49% | -$556K |
2020 Q4
18 quarters
|
|
2684
Cracker Barrel
CBRL
$1.28B
| $686K | ﹤0.01% |
+11,232
| New | +$566K |
2025 Q2
0 quarters
|
|
2685
iShares MSCI Emerging Markets Min Vol Factor ETF
EEMV
$3.57B
| $685K | ﹤0.01% |
+10,900
| New | +$656K |
2025 Q2
0 quarters
|
|
2686
Meridian
MRBK
$222M
| $682K | ﹤0.01% |
52,900
+14,900
| +39% | +$197K |
2020 Q3
19 quarters
|
|
2687
Alumis Inc
ALMS
$927M
| $680K | ﹤0.01% |
+226,815
| New | +$1.07M |
2025 Q2
0 quarters
|
|
2688
FNB Corp
FNB
$6.07B
| $675K | ﹤0.01% |
46,327
+29,300
| +172% | +$396K |
2024 Q3
3 quarters
|
|
2689
Franklin Financial Services
FRAF
$282M
| $675K | ﹤0.01% |
19,500
+8,800
| +82% | +$325K |
2023 Q4
6 quarters
|
|
2690
DELISTED
PROS Holdings
PRO
| $672K | ﹤0.01% |
+42,900
| New | +$730K |
2025 Q2
0 quarters
|
|
2691
Caribou Biosciences
CRBU
$49.3M
| $670K | ﹤0.01% |
+532,121
| New | +$523K |
2025 Q2
0 quarters
|
|
2692
Inovio Pharmaceuticals
INO
$119M
| $668K | ﹤0.01% |
328,129
+282,301
| +616% | +$541K |
2022 Q1
13 quarters
|
|
2693
Morgan Stanley Direct Lending Fund
MSDL
$1.13B
| $667K | ﹤0.01% |
35,620
+20,856
| +141% | +$403K |
2024 Q3
3 quarters
|
|
2694
TMC The Metals Company
TMC
$1.48B
| $666K | ﹤0.01% |
100,900
-408,100
| -80% | -$1.57M |
2025 Q1
1 quarter
|
|
2695
Thryv Holdings
THRY
$62.7M
| $663K | ﹤0.01% |
54,500
-141,800
| -72% | -$1.83M |
2024 Q2
4 quarters
|
|
2696
Oak Valley Bancorp
OVLY
$281M
| $661K | ﹤0.01% |
24,273
-4,000
| -14% | -$102K |
2019 Q4
22 quarters
|
|
2697
Corvus Pharmaceuticals
CRVS
$885M
| $661K | ﹤0.01% |
165,188
-99,800
| -38% | -$363K |
2017 Q1
33 quarters
|
|
2698
PLAYSTUDIOS Inc
MYPS
$49.4M
| $660K | ﹤0.01% |
50,360
+3,170
| +7% | +$43.5K |
2022 Q2
12 quarters
|
|
2699
Unity Bancorp
UNTY
$546M
| $659K | ﹤0.01% |
14,000
+800
| +6% | +$34.5K |
2017 Q2
32 quarters
|
|
2700
MGP Ingredients
MGPI
$295M
| $659K | ﹤0.01% |
+21,973
| New | +$653K |
2025 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.